Európska únia - slovenčina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

Európska únia - slovenčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - deferasirox - iron overload; beta-thalassemia - všetky ostatné terapeutické výrobky, Železo chelatačné činidlá - deferasirox dohode je indikovaný na liečbu chronického preťaženia železom vzhľadom na časté krvné transfúzie (≥7 ml/kg/mesiac balené červených krviniek) u pacientov s beta thalassaemia major vo veku 6 rokov a starších. deferasirox dohode je taktiež indikovaný na liečbu chronického preťaženia železom v dôsledku krvnej transfúzie, ak deferoxamínu terapia je kontraindikovaný alebo je nedostatočné v týchto skupín pacientov:v pediatrických pacientov s beta thalassaemia hlavných s preťaženia železom vzhľadom na časté krvné transfúzie (≥7 ml/kg/mesiac balené červených krviniek) vo veku 2 až 5 rokov,u dospelých a pediatrických pacientov s beta thalassaemia hlavných s preťaženia železom kvôli zriedkavé krvné transfúzie (.

Európska únia - slovenčina - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vakcíny - aktívna imunizácia proti ochorenie spôsobené streptococcus pneumoniae sérotypy 4, 6b, 9v, 14, 18 c, 19f a 23f (vrátane sepsy, meningitídy, pneumónia, bakterémia a akútna otitis media) u dojčiat a detí od dvoch mesiacov až päť rokov. použitie prevenar by mali byť stanovené na základe oficiálnych odporúčaní, berúc do úvahy vplyv invazívnych ochorení v rôznych vekových skupinách, ako aj variabilita sérotyp epidemiológie v rôznych geografických oblastiach.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - donepezil - 06 - psychostimulantia (nootropne lieČ., analeptika)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - donepezil - 06 - psychostimulantia (nootropne lieČ., analeptika)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - cytarabín - 44 - cytostatica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - betahistín - 83 - vasodilatantia

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - fulvestrant - 34 - antihormona

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

accord healthcare polska sp. z o.o., poľsko - tadalafil - 83 - vasodilatantia